Royalty Pharma plc (RPRX) Tops Q2 Revenue Estimate
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $58.43 -1%
Financial Fact:
Total revenues and other income: 10K
Today's EPS Names:
HFBL, PBHC, PBNK, More
Financial Fact:
Total revenues and other income: 10K
Today's EPS Names:
HFBL, PBHC, PBNK, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.
GUIDANCE:
Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
- Madrigal Pharma (MDGL) Tops Q2 EPS by 76c
- Gates Industrial Corporation plc (GTES) Tops Q2 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
